Pasithea Therapeutics Corp. (KTTA) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing treatments for RASopathies and MAPK pathway-driven tumors. The company's lead candidate, PAS-004, is a MEK inhibitor currently in Phase 1/1b trials for neurofibromatosis type 1 (NF1). The company is classified as a Smaller Reporting Company and an Emerging Growth Company.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(5.27) million | $(8.14) million | N/A |
| Loss Per Share (Diluted) | $(0.16) | $(0.29) | N/A |
| Operating Expenses | $(5.71) million | $(10.59) million | N/A |
| Cash & Equivalents | N/A | N/A | $45.66 million |
| Working Capital | N/A | N/A | $46.41 million |
| Total Liabilities | N/A | N/A | $1.87 million |
| Accumulated Deficit | N/A | N/A | $(78.15) million |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 49.9% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 41.4% year-to-date. This was driven primarily by a 71.5% increase in Research and Development (R&D) expenses due to clinical trial, CMC, and non-clinical research costs for PAS-004.
- Other Income: Net other income increased significantly by 363.8% in Q2 and 1,055.8% YTD. This was largely due to a $1.55 million gain from the change in fair value of warrant liabilities (specifically the reclassification of Placement Agent Warrants from liability to equity) and increased interest/dividend income.
- Warrant Liability Reclassification: In Q1 2026, following an increase in authorized shares, the company reclassified $2.29 million of Placement Agent Warrant liabilities to equity, resulting in a non-cash gain of $1.55 million recorded in the statement of operations.
- Cash Position: Cash and cash equivalents decreased by approximately $9.5 million during the six months ended June 30, 2026, primarily due to cash used in operating activities and an increase in prepaid expenses.
Outlook, Risks, and Management Commentary
- Liquidity: Management estimates that current cash resources ($45.7 million) are sufficient to fund operations for at least the next 12 months. However, the company remains dependent on additional equity or debt financing to continue development plans.
- Capital Raising: The company's At-The-Market (ATM) agreement was deregistered in January 2026, and no shares were sold under this agreement in the current period. The company has significant pre-funded warrants outstanding (54.8 million shares) that are immediately exercisable.
- R&D Outlook: R&D expenses are expected to continue increasing in fiscal year 2026 due to ongoing clinical trials for PAS-004, CMC costs, and personnel expansion.
- Risks: Key risks include the need for significant additional capital, the uncertainty of clinical trial outcomes, and the company's history of operating losses. The company has no revenue and relies entirely on financing activities.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $45.7 million cash balance against the accelerating burn rate (approx. $9.5 million cash used in 6 months).
- Warrant Overhang: Assess the potential dilution from 54.8 million pre-funded warrants and 11.9 million other warrants outstanding.
- ATM Status: Confirm the status of the deregistered ATM agreement and the company's ability to access capital markets without it.
- Non-Cash Gains: Note that the significant improvement in "Other Income" was driven by non-cash warrant liability reclassifications, not operational performance.
- Expense Trajectory: Monitor the 70%+ increase in R&D spend to ensure it aligns with clinical milestones for PAS-004.